New SGLT2 Inhibitor Gains FDA Approval for Type 2 Diabetes
(MedPage Today) -- The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats is now approved for humans with the disease, drugmaker TheracosBio announced.
As an adjunct to diet and exercise, the oral treatment is indicated... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 23, 2023 Category: Cardiology Source Type: news
Diabetes Drug for Cats Now Approved in Humans Too
(MedPage Today) -- The first oral SGLT2 inhibitor approved by the FDA for treating diabetes in cats is now approved for humans with the disease, drugmaker TheracosBio announced.
As an adjunct to diet and exercise, the oral treatment is indicated... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 23, 2023 Category: Primary Care Source Type: news
The Year SGLT2 Inhibitors Became Full-Fledged Heart Failure Drugs
(MedPage Today) -- Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we follow up on what has happened... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 27, 2022 Category: Urology & Nephrology Source Type: news
Dec 2 2022 This Week in Cardiology Dec 2 2022 This Week in Cardiology
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 2, 2022 Category: Transplant Surgery Tags: Cardiology Commentary Source Type: news
EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD
Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 22, 2022 Category: Respiratory Medicine Tags: Nephrology News Source Type: news
SGLT2 Inhibitors Safe After Revascularization for Limb Disease SGLT2 Inhibitors Safe After Revascularization for Limb Disease
In patients with type 2 diabetes and peripheral artery disease who undergo revascularization, cardiovascular and renal benefits of the agents were confirmed without increased risk of limb amputation.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 4, 2022 Category: Internal Medicine Tags: Nephrology News Source Type: news
SGLT2 Inhibitor Role for Isolated Kidney Disease SGLT2 Inhibitor Role for Isolated Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2022 Category: Cardiology Tags: Nephrology News Source Type: news
Empagliflozin and Elderly Patients With HFpEF Empagliflozin and Elderly Patients With HFpEF
Do elderly patients with HFpEF benefit as much as younger patients from treatment with an SGLT2 inhibitor? A new study demonstrates its efficacy across all age groups.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF Dapagliflozin DELIVERs Regardless of BP in Preserved-EF HF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with HF might present a hazard to those with a low systolic BP, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy Newer Drugs Not Cost-Effective for First-Line Diabetes Therapy
Costs of SGLT2 inhibitors and GLP-1 receptor agonists ' need to be lowered substantially ' to improve health outcomes and prevent health disparities in patients with type 2 diabetes, say researchers.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 4, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
(MedPage Today) -- Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study.
Compared with traditional first-line metformin, first... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2022 Category: Cardiology Source Type: news
Urgency to Expand SGLT2i Use in HF Heightened by More DELIVER Data
(MedPage Today) -- NATIONAL HARBOR, Md. -- The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for heart failure (HF) patients... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2022 Category: Cardiology Source Type: news
Incidence of Dry Eye Disease Lower With SGLT2 Inhibitors
(MedPage Today) -- A potential benefit of SGLT2 inhibitors in patients with type 2 diabetes (T2D) may be reduced incidence of dry eye disease, said authors of a large retrospective study.
In more than 10,000 patients followed for approximately... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 24, 2022 Category: Endocrinology Source Type: news
